# Our Human Pharma Research and Development Pipeline



This represents a selection of assets under investigation in our research and development portfolio in June 2023.



Potential **first-in**class assets anchor an innovation led portfolio



New phase II and phase III starts over the next 12-18 months



therapy approvals seven years




Of pipeline anchored in external collaborations\*

\*Across research, pre-clinical and clinical portfolios

# PHASE 1

► NPY2r agonist*†	GLP-1/FGF21 agonist	
Heart disease modulator*	B7-H6/CD3 T-cell engager*	
CD137/FAP agonist*	DLL3/CD3 T-cell engager*	
<b>Ezabenlimab</b> <sup>†</sup> PD-1 antibody	HER2 TKI	
KISIMA® cancer vaccine*†	pan KRAS SOS1 inhibitor*†	
Brigimadlin* MDM2-p53 antagonist	SIRP $\alpha$ antagonist	
<ul> <li>STING agonist (2nd generation)</li> </ul>	VSV-GP	
Anti-fibrotic agent*	lon channel inhibitor	
Lysophospholipase inhibitor	PD-1 antibody	
► TREM-1 antibody	NMDA regulator	
Phospholipid modulator	Vascular modulator	

## PHASE 2




† Being investigated in combination with other therapies. Key Pipeline Advances (January – June 2023)

Breakthrough Therapy Designation granted by the U.S. Food and Drug Administration.

#### Indication abbreviations:

2L+BTC	2nd line treatment, advanced biliary tract cancer	HF HS
CD	Crohn's disease	IPF
CIAS	Cognitive impairment associated with schizophrenia	MDD MI
CKD CSPH DDLPS DR FSGS GPP	Chronic kidney disease Clinically significant portal hypertension Dedifferentiated liposarcoma Diabetic Retinopathy Focal segmental glomerulosclerosis Generalized pustular psoriasis	NASH nCFB PPF PTSD SSc

## PHASE 3



## REGISTRATION

**Spesolimab** Ð Empagliflozin\* / (BI 655130) **New indication** IL36R antibody | GPP SGLT2 inhibitor | CKD flare prevention

#### Кеу

- Cardio-Renal-Metabolic Diseases
- Oncology
  - Respiratory Diseases
  - lmmunology
  - Central Nervous System Diseases
- Retinal Diseases
- \*Partnered projects or acquired assets.
- \*\*Prevention of HF post MI
- Fast Track Designation granted by the U.S. Food and Drug Administration
- Heart failure Hidradenitis suppurativa Idiopathic pulmonary fibrosis Major depressive disorder Myocardial infarction Non-alcoholic steatohepatitis non-cystic fibrosis bronchiectasis Progressive pulmonary fibrosis Post-traumatic stress disorder Systemic sclerosis

## CARDIO-RENAL-METABOLIC DISEASES

Building on our legacy of innovative treatments for a range of cardiovascular, renal and metabolic conditions, our R&D strategy takes a holistic view of the needs of people with metabolic diseases such as diabetes, who often have multiple, related conditions. We are pursuing the next wave of innovative medicines for obesity, kidney and liver diseases - including non-alcoholic steatohepatitis (NASH).

#### **ONCOLOGY**

We have a clear aspiration - to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity



We are building on a heritage of more than a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrotic interstitial lung diseases. Our R&D approach leverages our deep understanding and extensive expertise in respiratory medicine, inflammation and fibrosis to develop the next generation of innovative therapies for patients with a broad



Our R&D strategy is inspired by the courage of patients living with debilitating, life-limiting auto-immune conditions. We are taking bold steps to deliver scientific breakthroughs that target, repair and prevent these diseases. Specific areas of focus include inflammatory skin diseases and inflammatory bowel diseases such as Crohn's Disease and Ulcerative Colitis.

of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.



We are redefining mental health to enable people to thrive. We link behavior to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment with new and innovative approaches and technologies, we aim to enable those with mental health conditions to create more meaningful connections to their lives, loved ones and society.

range of lung diseases who have a high unmet medical need.



The ambition to prevent vision loss in people at risk, and preserve or restore vision in those with retinal diseases, is at the core of our R&D activities. Our extensive knowledge and insights from other therapeutic areas enable us to tackle the multifactorial pathophysiology of retinal diseases. Areas of focus include wet age-related macular degeneration, diabetic retinopathy and geographic atrophy.

In addition to building on our strengths in core therapeutic areas, we capture synergies by focusing research platforms on mechanisms such as immune modulation and fibrosis that contribute to multiple diseases. We focus expertise and resources to discover common pathophysiological mechanisms and accelerate the development of new medicines.

Our Research Beyond Borders function is exploring new frontiers in science and technology, both within and beyond our core therapeutic areas, to anticipate future trends in biomedical research and bring transformative advances to patients.

